Patents Expiring in December 2045
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-001 | Jul 26, 2024 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-002 | Jul 26, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ||||
| Alpha Cognition | ZUNVEYL | benzgalantamine gluconate | TABLET, DELAYED RELEASE;ORAL | 218549-003 | Jul 26, 2024 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE | ||||
| Bayer Hlthcare | LYNKUET | elinzanetant | CAPSULE;ORAL | 219469-001 | Oct 24, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE BY ADMINISTERING 60 MG (ONE CAPSULE) OF LYNKUET ORALLY ONCE DAILY AT BEDTIME CONCOMITANTLY WITH A MODERATE CYP3A4 INHIBITOR | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
